Publications by authors named "Susanne Saussele"

64Publications

Separase activity distribution can be a marker of major molecular response and proliferation of CD34 cells in TKI-treated chronic myeloid leukemia patients.

Ann Hematol 2020 May 6;99(5):991-1006. Epub 2020 Apr 6.

Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04007-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196950PMC
May 2020

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.

Leuk Res 2020 03 23;90:106310. Epub 2020 Jan 23.

Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Section of Hematology, Uppsala University Hospital, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2020.106310DOI Listing
March 2020

DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia.

Int J Mol Sci 2020 Feb 11;21(4). Epub 2020 Feb 11.

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21041177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072846PMC
February 2020

Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML.

Cancer Res 2020 06 10;80(11):2394-2406. Epub 2020 Feb 10.

Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-2175DOI Listing
June 2020

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Haematologica 2019 05 4;104(5):955-962. Epub 2018 Dec 4.

Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität München, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.206797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518910PMC
May 2019

Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.

Cancer 2017 Jul 13;123(13):2467-2471. Epub 2017 Feb 13.

Institute for Medical Information Sciences, Biometry, and Epidemiology (IBE), Ludwig-Maximilians University, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30636DOI Listing
July 2017

Management of CML-blast crisis.

Best Pract Res Clin Haematol 2016 09 20;29(3):295-307. Epub 2016 Oct 20.

Division of Hematology/Medical Oncology, Weill Cornell Medical College, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.10.005DOI Listing
September 2016

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

J Natl Cancer Inst 2016 Jul 4;108(7). Epub 2016 Mar 4.

Affiliations of authors:Department of Health Policy and Management, Johns Hopkins University , Baltimore, MD (WVP); Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL; Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center , and Cecil G. Sheps Center for Health Services Research, University of North Carolina , Chapel Hill, NC (SBD); Department of Haematology, Hammersmith Hospital, Imperial College , London , UK (JFA); Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany; Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna , Bologna , Italy ; Department of Haematology and Oncology, University Hospital , Jena , Germany (EE); INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG); Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM); Department of Internal Medicine, Hematology and Oncology, University Hospital Brno , Brno , Czech Republic (JM); Department of Hematology and Oncology, University Hospital Leipzig , Leipzig , Germany (DN); Barbara Ann Karmanos Cancer Institute, Wayne State University , Detroit, MI (CAS); Department of Medicine, Weill Cornell Medical Center , New York, NY (RTS); Uppsala University , Uppsala , Sweden (BS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948567PMC
July 2016

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.

J Cancer Res Clin Oncol 2014 Nov 22;140(11):1965-9. Epub 2014 Jun 22.

Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-014-1746-8DOI Listing
November 2014

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

J Clin Oncol 2014 Feb 2;32(5):415-23. Epub 2013 Dec 2.

Rüdiger Hehlmann, Martin C. Müller, Benjamin Hanfstein, Alice Fabarius, Annette Schreiber, Ulrike Proetel, Nadine Pletsch, Susanne Saußele, Universitätsmedizin Mannheim Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim; Jolanta Dengler Universitätsklinikum Heidelberg, Heidelberg; Michael Lauseker, Markus Pfirrmann, Joerg Hasford, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universität; Christoph Nerl, Städtisches Klinikum Munchen Schwabing; Hans-Jochem Kolb, Klinikum rechts der Isar, Technische Universität München; Karsten Spiekermann, Universitätsklinikum, Ludwig-Maximilians Universität München; Claudia Haferlach, Susanne Schnittger, MLL Münchner Leukämielabor, Munich; Hermann Einsele, Universitätsklinikum Würzburg, Würzburg; Christiane Falge, Klinikum Nürnberg Nord, Nuremberg; Lothar Kanz, Universitätsklinikum Tübingen, Tübingen; Andreas Neubauer, Universitätsklinikum Gießen und Marburg, Marburg; Michael Kneba, Universitätsklinikum Schleswig-Holstein, Kiel; Frank Stegelmann, Hermann Heimpel, Universitätsklinikum Ulm, Ulm; Michael Pfreundschuh, Universitätsklinikum des Saarlandes, Homburg/Saar; Cornelius F. Waller, Universitätsklinikum Freiburg, Freiburg; Gerhard Ehninger, Universitätsklinikum Carl Gustav Carus, Dresden; Stefan W. Krause, Universitätsklinikum Erlangen, Erlangen; Dieter K. Hossfeld, Universitätsklinikum Eppendorf, Hamburg; Andreas Hochhaus, Universitätsklinikum Jena, Jena, Germany; Gabriela M. Baerlocher, Inselspital Bern, Bern; Dominik Heim, Universitätsspital Basel, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.9020DOI Listing
February 2014

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.

Ann Hematol 2013 Oct 28;92(10):1345-50. Epub 2013 Apr 28.

Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, 07740 Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-013-1769-2DOI Listing
October 2013

[Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials].

Onkologie 2013 ;36 Suppl 2:23-8

Kompetenznetz Leukämien, Medizinische Klinik II, Hämatologie und Onkologie, Studienzentrale, Klinikum der Goethe-Universität, Frankfurt a.M., Deutschland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000348254DOI Listing
September 2013

Clinical trials in chronic myeloid leukemia.

Curr Hematol Malig Rep 2012 Jun;7(2):109-15

Universitätsmedizin Mannheim, Universität Heidelberg, III. Medizinische Klinik, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-012-0118-1
Publisher Site
http://dx.doi.org/10.1007/s11899-012-0118-1DOI Listing
June 2012

Treatment of chronic myeloid leukemia when imatinib fails.

Expert Opin Pharmacother 2011 Feb;12(2):269-83

III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Pettenkoferstrasse 22, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2011.533169DOI Listing
February 2011

Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia.

Genes Chromosomes Cancer 2010 May;49(5):471-9

Pathologisches Institut, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20757DOI Listing
May 2010

[Clinical research within the German competence net "acute and chronic leukemias"].

Med Klin (Munich) 2006 May;101(5):414-20

Netzwerkzentrale des Kompetenznetzes "Akute und chronische Leukämien", III. Medizinische Universitätsklinik, Klinikum Mannheim der Universität Heidelberg, Mannheim.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00063-006-1056-2DOI Listing
May 2006

Treatment concepts of acute promyelocytic leukemia.

Crit Rev Oncol Hematol 2005 Nov 19;56(2):261-74. Epub 2005 Oct 19.

Medizinische Universitätsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Wiesbadener Str. 7-11, 68305 Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2004.08.009DOI Listing
November 2005

Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.

Anticancer Drugs 2005 Jan;16(1):39-45

Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200501000-00005DOI Listing
January 2005

Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia.

Genes Chromosomes Cancer 2003 Feb;36(2):175-88

III. Medizinische Universitätsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin der Universität Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.10154DOI Listing
February 2003